Impact of Biologic Therapy on the Small Airways Asthma Phenotype

Rory Chan · Brian J. Lipworth

Received: 18 July 2022 / Accepted: 27 September 2022 / Published online: 14 October 2022
© The Author(s) 2022

Abstract
The small airways dysfunction (SAD) asthma phenotype is characterised by narrowing of airways < 2 mm in diameter between generations 8 and 23 of the bronchial tree. Recently, this has become particularly relevant as measurements of small airways using airway oscillometry for example, are strong determinants of asthma control and exacerbations in moderate-to-severe asthma. The small airways can be assessed using spirometry as forced expiratory flow rate between 25 and 75% of forced vital capacity (FEF_{25–75}) and has been deemed more accurate in detecting small airways dysfunction than forced expiratory volume in 1 s (FEV_{1}) [3]. Having said that FEF_{25–75} is rather volume dependent in terms of ensuring patients breathe out all the way to residual volume and as such is considered to be more variable.

Oscillometry as the heterogeneity in resistance between 5 and 20 Hz (R_{5–20}), low frequency reactance at 5 Hz (X_{5}) or area under the reactance curve between 5 Hz and the resonant frequency can also be used to assess the small airways. The small airways can also be assessed using the multiple breath nitrogen washout (MBNW) test giving rise to values including functional residual capacity, lung clearance index and ventilation distribution heterogeneity in the conducting (S_{cond}) and the acinar (S_{acin}) airways. The ATLANTIS group showed that the prevalence of small airways disease in asthma defined on FEF_{25–75}, oscillometry and MBNW all increased with progressive GINA asthma disease stages. As opposed to topical inhaler therapy that might not adequately penetrate the small airways, it is perhaps more intuitive that systemic anti-inflammatory therapy with biologics targeting downstream cytokines and upstream epithelial anti–alarmins may offer a promising solution to SAD. Here we therefore aim to appraise the available evidence for the effect of anti-IgE, anti-IL5 (Rα), anti-IL4Rα, anti-TSLP and anti-IL33 biologics on small airways disease in patients with severe asthma.

Keywords Small airways · Severe asthma · FEF_{25–75} · Oscillometry · Multiple breath nitrogen washout · Omalizumab · Mepolizumab · Reslizumab · Benralizumab · Dupilumab · Tezepelumab · Itepekimab

Introduction
The small airways dysfunction (SAD) asthma phenotype is characterised by narrowing of airways < 2 mm in diameter between generations 8 and 23 of the bronchial tree [1]. Recently, this has become particularly relevant as measurements of small airways using airway oscillometry for example, are strong determinants of asthma control and exacerbations in moderate-to-severe asthma [2]. The small airways can be assessed using spirometry as forced expiratory flow rate between 25 and 75% of forced vital capacity (FEF_{25–75}) and has been deemed more accurate in detecting small airways dysfunction than forced expiratory volume in 1 s (FEV_{1}) [3].
measure of anatomical narrowing of the small airways [8]. Contemporaneously, it has been determined that combining both spirometry and oscillometry measurements might better identify moderate-to-severe asthma patients with worse control and more frequent exacerbations [9, 10].

The small airways can also be assessed using the multiple breath nitrogen washout (MBNW) test giving rise to values including functional residual capacity, lung clearance index and ventilation distribution heterogeneity in the conducting (Sccond) and the acinar (Sacin) airways [11]. The ATLANTIS group showed that the prevalence of small airways disease in asthma defined on FEF_{25-75}, oscillometry and MBNW all increased with progressive GINA asthma disease stages [12].

The peripheral airways have previously been termed the quiet zone of the lung because they are difficult to assess and treat. Conventional high doses of inhaled corticosteroids have been shown to be relatively ineffective in managing distal lung inflammation measured by alveolar nitric oxide [13]. This is likely attributed to aerosols comprising a larger particle size that have a predilection to deposit in the large airways [14]. In one study, adding extra-fine HFA–BDP on top of high dose conventional particle fluticasone/salmeterol conferred no improvement in oscillometry small airways function or alveolar NO in patients with severe persistent asthma [15]. Over the past decade, type 2 biologic therapies have been shown to significantly improve exacerbations and other clinical outcomes such as disease control, pulmonary function and type 2 biomarkers [16, 17].

Here we therefore aim to appraise the available evidence for the effect of systemic biologic therapies on small airways disease in patients with severe asthma. We searched PubMed and Google Scholar for terms including “small airways”, “omalizumab”, “mepolizumab”, “benralizumab”, “reslizumab”, “dupilumab”, “tezepelumab”, “itepekimab”, “FEF_{25-75}”, “oscillometry” and “multiple breath nitrogen washout” with abstracts and case reports excluded. The aim here is not to perform a systematic review or meta-analysis as the investigated outcomes in these cited studies are too heterogenous to amalgamate. The essential premise here is that the systemic route of administration would facilitate delivery of biologics to the whole lung including the peripheral airways in the same way as oral corticosteroids in patients who are refractory to high dose ICS. Given that the airway mucusal surface area is proportionately much greater in the distal compared to proximal lung, systemic delivery of biologics appears to be a cogent way for treating all of the type 2 inflammation in asthmatic airways. Indeed, this may be one of the reasons why systemic biologics are so successful at improving control in severe asthma patients despite the use of high dose inhaled combination therapy.

### Omalizumab

Omalizumab is a recombinant humanised anti-IgE monoclonal IgG1 antibody that blocks the binding of free IgE to its high affinity FceRI receptor on mast cells and basophils [18]. It has the secondary action of binding to membrane bound IgE (mIgE) on mIgE-expressing B cells resulting in downregulation of IgE production [19]. A Cochrane review has demonstrated significant reductions in exacerbations and hospitalisations in moderate-to-severe asthma [20]. As FceRI expression is increased throughout the large and small airways in severe asthma [21], one might postulate that a systemic therapy such as omalizumab would confer additional benefit to allergic patients only taking topical inhaler therapy.

A retrospective cohort study (n = 110) in adult patients with severe eosinophilic allergic asthma showed that omalizumab significantly improved FEF_{25-75} by 8.3% over 52 weeks [22]. Another real-life retrospective clinical study (n = 20) of severe asthma patients demonstrated that omalizumab significantly improves FEF_{25-75} by 6% but not FEV_{1}/FVC by 4%, over 44 weeks along with clinically significant reductions in exacerbations and ACQ scores [23]. A prospective observational study (n = 26) also highlighted an improvement in alveolar nitric oxide levels in severe asthmatics following 48 weeks of omalizumab indicating a potential therapeutic effect on small airways type 2 inflammation [24]. This is important as uncontrolled small airways inflammation is related to airway remodelling and progression of disease [25]. Additionally, patients with aspirin exacerbated respiratory disease generally have higher levels of type 2 inflammation [26], and in one small case series (n = 4) such patients also experienced improvements in FEF_{25-75} by 30% [27]. No studies have been performed looking at the effect of omalizumab therapy on other measures of small airways disease.

### Mepolizumab, Reslizumab and Benralizumab

Mepolizumab and Reslizumab are humanised IgG1κ and IgG4κ monoclonal antibodies, respectively, that exert its effect by inhibiting interleukin 5 attachment to the IL5Rα receptor on eosinophils [28, 29]. Benralizumab is a humanised IgG1κ monoclonal antibody that binds to the IL5Rα receptor on eosinophils to prevent IL5 activation [30]. Through this shared mechanism of action, suppression or depletion of eosinophilic activation, proliferation and migration is achieved. Due to higher expression of IL5 mRNA in the small airways (< 2 mm diameter) in asthmatics, one might expect mepolizumab, reslizumab and benralizumab therapy to be effective in SAD [31].
The phase 3b RCT MUSCA demonstrated significant improvements in FEF25–75% amounting to 0.123 L/s after 24 weeks of mepolizumab vs placebo in $n = 551$ patients with severe eosinophilic asthma [32]. Although this is the largest study investigating the effect of mepolizumab in small airways, MUSCA was not powered a priori on FEF25–75% [32]. To support this, two retrospective studies ($n = 134$ and $n = 105$) independently demonstrated a significant improvement in FEF25–75% with mepolizumab in severe eosinophilic asthma patients with respective improvements of 9.8% and 8.1% [33, 34]. Smaller observational studies [23, 35] ($n = 31$ and $n = 30$) have shown no improvement in FEF25–75% after 24–44 weeks of mepolizumab. However, the mean baseline FEF25–75% in these smaller studies were higher and therefore there may have been less room for improvement.

In a prospective study ($n = 18$), it was shown that oscillometry low frequency reactance as X5, a measure of peripheral lung compliance, significantly improved by 74% one month post mepolizumab therapy in severe eosinophilic asthma [36]. However, another retrospective study in severe asthmatics ($n = 30$) showed no improvements in R5–R20 or AX following 10 months of mepolizumab [23]. These studies are likely to be underpowered to draw any meaningful conclusions. One prospective cohort study ($n = 20$) showed a significant improvement in small airway function after 26 weeks with mepolizumab measured by ventilation heterogeneity as Sac in using MBNW in patients with severe eosinophilic asthma [37].

In a phase 3 randomised controlled trial (RCT) ($n = 205$) [38], there was a borderline significant trend for iv reslizumab 3 mg/kg to improve FEF25–75% over 16 weeks by 0.233 L/s vs placebo, exceeding the established biological variability in severe asthma of 0.21 L/s [39] to infer a clinically relevant treatment effect. An open label extension study ($n = 1051$) has shown that these FEF25–75% improvements persist up to 96 weeks on reslizumab in patients with moderate-to-severe asthma [40]. Post hoc analysis of 2 phase 3 RCTs ($n = 723$) in severe eosinophilic asthma showed that reslizumab significantly improves FEF25–75% over placebo with a mean difference 0.128 L/s [41]. Although reslizumab is used in clinical practice to a lesser extent, we postulate that these encouraging results can possibly be extrapolated to mepolizumab due to the shared immunological pathway. No studies to date have been performed on reslizumab looking at oscillometry or MBNW outcomes.

A multicentre retrospective observational study [42] ($n = 137$) looking at patients with severe eosinophilic asthma demonstrated significant improvements in FEF25–75% amounting to 17% after 24 weeks of benralizumab. Another real-life retrospective observational study [43] ($n = 22$) showed that benralizumab improved FEF25–75% by 0.82 L/s over 24 weeks in severe allergic eosinophilic asthma patients greatly exceeding the biological variability value [39] for a clinically relevant effect. In one prospective observational study with benralizumab in severe asthma [44] ($n = 19$) no improvements in R5–R20, X5 and AX were observed after 24 weeks. Pointedly, patients in this study started with normal small airways function and therefore one would perhaps not expect any improvement.

### Dupilumab

Dupilumab is a humanised IgG4 monoclonal antibody that targets the IL4Rα receptor to mediate IL4 and IL13 activity [45]. Interestingly, IL4 and IL13 but not IL5 have been shown to induce hyperresponsiveness in isolated small airways [46]. Additionally, more IL4 mRNA expression has been found in the small airways of asthmatic versus non-asthma patients [31].

The phase 3 LIBERTY ASTHMA QUEST trial [47] ($n = 1902$) in uncontrolled moderate-to-severe asthma showed that FEF25–75 significantly improved by 0.16 L/s following 52 weeks of dupilumab treatment compared to placebo. In this regard, a phase 2 RCT [48] ($n = 148$) in moderate-to-severe asthma also showed that dupilumab improved FEF25–75% by 0.19 L/s compared to placebo over 12 weeks albeit the significance was not reported here since it was not the primary outcome. In another prospective cohort study [49] ($n = 20$) of severe asthma patients with nasal polyps treated with dupilumab for 4 weeks there was a significant improvement in FEF25–75% of 0.33 L/s exceeding biological variability. In terms of airway oscillometry, one retrospective study [50] ($n = 62$) in mild-to-moderate asthma with concomitant CRSwNP showed that 3 months of dupilumab therapy did not significantly change X5.

### Tezepelumab

Tezepelumab is a humanised IgG2α monoclonal antibody that blocks the upstream epithelial alarmin thymic stromal lymphopoietin (TSLP) from interacting with the TSLP receptor complex resulting in dampening of the type 2 inflammatory response [51]. The phase 2 CASCADE trial [52] ($n = 110$) in moderate-to-severe uncontrolled asthma demonstrated no improvement in FEF25–75 or R5–R20 over placebo although interestingly tezepelumab resulted in a 0.56 kPa/L improvement in AX that exceeds the biological variability value of 0.39 kPa/L in severe asthma [39].

### Itepekimab

Itepekimab is a humanised IgG4 monoclonal antibody with anti-alarmin activity against IL-33 resulting in suppression of type 2 inflammation [48]. In a phase 2 RCT of moderate-to-severe asthmatics ($n = 148$) [48], itepekimab was shown...
to improve FEF_{25-75} by 0.170 L/s over 12 weeks compared to placebo, which did not exceed the biological variability value. In this regard, the same phase 2 RCT [48] with combined itepekimab and dupilumab conferred a 0.120 L/s improvement in FEF_{25-75} over placebo which was numerically less than for itepekimab or dupilumab alone. This suggests that merely blocking more type 2 inflammatory pathways may not be the answer. The effect of various biologic therapies on FEF_{25-75} is summarised in tabular form (Table 1).

### Conclusions

Prospective RCTs with various biologics are now indicated which are properly powered on small airway outcomes, where patients are selected a priori on the basis of having clinically relevant degrees of SAD. We would duly suggest that such patients might exhibit values for spirometry as FEF_{25-75} < 50%, or oscillometry as X5 < −0.20 kPa/L/s, R5−20 ≥ 0.10 kPa/L/s or AX ≥ 1.0 kPa/L given that such values are associated with poor control and more frequent exacerbations [9, 53]. Ideally, future studies should take into consideration z-scores for FEF_{25-75} to account for differences in age and height although in a real-life busy clinic it is perhaps more pragmatic to use absolute cut offs. Oscillometry in particular is easy to perform and effort dependent with validated biological variability values and is therefore eminently suitable for powering such studies in the first instance. In this regard, the ongoing SASAM trial (NCT05040997) is using small airways disease measured by spirometry, body plethysmography, single and multiple breath nitrogen washout and impulse oscillometry as novel endpoints and distinct targets for mepolizumab. The problem for such a trial is deciding on which of the SAD outcomes should be selected as the primary end point in that patients with asthma may for example have relatively well–preserved spirometry with abnormal oscillometry [9, 53]. Another study (NCT03976310) is currently looking at the effects of benralizumab in air trapping, which can be considered a surrogate for small airways disease [10], on high resolution computed tomography imaging as the primary outcome. Tezepelumab is also presently being studied (NCT05280418) to look at its effect in ventilation heterogeneity on hyperpolarised 129Xe magnetic resonance imaging as the primary outcome.

### Author Contributions

RC and BL were jointly responsible for idea conception and writing all versions of the manuscript.

### Funding

The authors have not disclosed any funding.
Declarations

Conflict of interest Chan reports personal fees (talks) and support attending ERS from AstraZeneca and personal fees (talks) from Thora-sys. Lipworth reports non-financial support (equipment) from GSK; grants, personal fees (consulting, talks and advisory board), other support (attending ATS and ERS) and from AstraZeneca; personal fees (talks and consulting) from Sanoﬁ, personal fees (consulting, talks and advisory board) from Circassia in relation to the submitted work; grants, personal fees (consulting, talks, advisory board), other support (attending ERS) from Teva, personal fees (talks and consulting), grants and other support (attending ERS and BTS) from Chiesi, personal fees (consulting) from Lupin, personal fees (consulting) from Glenmark, personal fees (consulting) from Vectura, personal fees (consulting) from Reddy, personal fees (consulting) from Sandoz; grants, personal fees (consulting, talks, advisory board), other support (attending BTS) from Boehringer Ingelheim, grants and personal fees (advisory board and talks) from Mylan outside of the submitted work; and the son of BJL is presently an employee of AstraZeneca.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lipworth B, Manoharan A, Anderson W (2014) Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med 2(6):497–506
2. Chan R, Lipworth BJ (2022) Determinants of asthma control and exacerbations in moderate to severe asthma. J Allergy Clin Immunol Pract 10(10):2758–2760.e1. https://doi.org/10.1016/j.jaip.2022.06.042
3. Chiu HY, Hsieh YH, Su KC, Lee YC, Ko HK, Peng DW (2020) Small airway dysfunction by impulse oscillometry in symptomatic patients with preserved pulmonary function. J Allergy Clin Immunol Pract 8(1):229–35.e3
4. Cottini M, Licini A, Lombardi C, Berti A (2020) Clinical characterization and predictors of ios-defined small-airway dysfunction in asthma. J Allergy Clin Immunol Pract 8(3):997–1004.e2
5. Chan R, Lipworth BJ (2022) Oscillometry bronchodilator response in adult moderate to severe eosinophilic asthma patients: a prospective cohort study. Clin Exp Allergy 52(9):1118–1120. https://doi.org/10.1111/cea.14185
6. Kuo CR, Jabbals S, Lipworth B (2018) Is small airways dysfunction related to asthma control and type 2 inflammation? Ann Allergy Asthma Immunol 121(5):631–632
7. Jabbals S, Manoharan A, Lipworth J, Lipworth B (2016) Utility of impulse oscillometry in patients with moderate to severe persistent asthma. J Allergy Clin Immunol Pract 138(2):601–603
8. Foey BH, Soares M, Bordas R et al (2019) Lung computational models and the role of the small airways in asthma. Am J Respir Crit Care Med 200(8):982–991
9. Chan R, Lipworth BJ (2022) Combining low-frequency oscillometry and spirometry measurements in relation to asthma control and exacerbations in moderate-to-severe asthma. J Allergy Clin Immunol Pract 10(7):1910–1912.e1. https://doi.org/10.1016/j.jaip.2022.03.023
10. Chan R, Lipworth B (2022) Forced vital capacity and low frequency reactance area measurements are associated with asthma control and exacerbations. Lung 200(3):301–303
11. Robinson PD, Latzin P, Verbanck S et al (2013) Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J 41(3):507–522
12. Postma DS, Brightling C, Baldi S et al (2019) Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 7(5):402–416
13. Berry M, Hargadon B, Morgan A et al (2005) Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 25(6):986–991
14. Martin RJ (2002) Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol Pract 109(2 Suppl):S447–S460
15. Williamson PA, Short PM, Vaidyanathan S, Lipworth BJ (2013) Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol 75(1):93–102
16. Chan R, RuiWen Kuo C, Lipworth B (2020) Pragmatic clinical perspective on biology for severe refractory type 2 asthma. J Allergy Clin Immunol Pract 8(10):3363–3370. https://doi.org/10.1016/j.jaip.2020.06.048
17. Chan R, Stewart K, Misirios R, Lipworth B (2022) Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract. https://doi.org/10.1016/j.jaip.2022.01.040
18. Weiler CR (2019) Omalizumab and mast cell disorders: are we there yet? J Allergy Clin Immunol Pract 7(7):2396–2397
19. Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18(2):157–162
20. Normansell R, Walker S, Milan SJ, Walters EH, Nair P (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 13(1):CD003559
21. Den Otter I, Silva LFF, Carvalho ALN et al (2010) High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. Clin Exp Allergy 40(10):1473–1481
22. Huang W-C, Fu P-K, Chan M-C et al (2021) The long-term effectiveness of omalizumab in adult patients with severe allergic asthma: continuous treatment versus boosting treatment. J Clin Med 10(4):707
23. Chan R, RuiWen Kuo C, Lipworth B (2021) Real-life small airway outcomes in severe asthma patients receiving biologic therapies. J Allergy Clin Immunol Pract 9(7):2907–2909
24. Tajiri T, Niimi A, Matsumoto H et al (2014) Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol 113(4):470–5.e2
25. Bjerner L (2014) The role of small airway disease in asthma. Curr Opin Pulm Med 20(1):23–30
26. Chan R, Lipworth B (2021) Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma. Ann Allergy Asthma Immunol 127(5):548–552. https://doi.org/10.1016/j.anai.2021.06.007
27. Cameli P, Perruzza M, Salvini M et al (2019) Omalizumab treatment for Samter's triad: case series and review of the literature. Eur Respir J 50(4):1016/j.anai.2020.06.048
28. Pelaia C, Vatrella A, Busceti MT et al (2017) Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther 11:3137–3144
29. della Porta G, Cinti E, F magazine: relationship between airflow obstruction and peripheral blood eosinophils. J Allergy Clin Immunol Pract. https://doi.org/10.1016/j.jaip.2020.06.048
30. Maldonado C, Varela A, Busceti MT et al (2017) Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther 11:3137–3144
31. della Porta G, Cinti E, F magazine: relationship between airflow obstruction and peripheral blood eosinophils. J Allergy Clin Immunol Pract. https://doi.org/10.1016/j.jaip.2020.06.048
32. Maldonado C, Varela A, Busceti MT et al (2017) Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther 11:3137–3144
29. Pelaia G, Vatrella A, Busceti MT et al (2016) Role of biologics in severe eosinophilic asthma—focus on reslizumab. Ther Clin Risk Manag 12:1075–1082
30. Pelaia C, Calabrese C, Vatrella A et al (2018) Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int 2018:4839230
31. Tulic MK, Christodoulopoulos P, Hamid Q (2001) Small airway inflammation in asthma. Respir Res 2(6):333
32. Chupp GL, Bradford ES, Albers FC et al (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5(5):390–400
33. Sposato B, Camiciotto G, Bacci E et al (2020) Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulm Pharmacol Ther 61:101899
34. Maglio A, Vitale C, Pellegrino S, Calabrese C, D’Amato M, Molino A, Pelaia C, Triggiani M, Pelaia G, Stellaio C, Vatrella A (2021) Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma. Biomedicines 9(11):1550. https://doi.org/10.3390/biomedicines9111550
35. Yılmaz İ, Nazik Bahçecioğlu S, Türk M, Tutar N, Paçaci Çetin G, Arslan B (2021) Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turk J Med Sci 51(4):1953–1959
36. Antoncicelli L, Tontini C, Marchionni A, Lucechetti B, Garritani MS, Bilò MB (2020) Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma. Allergy 75(2):433–436
37. Farah CS, Badal T, Reed N et al (2019) Mepolizumab improves small airway function in severe eosinophilic asthma. Respir Med 148:49–53
38. Bjørner L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M (2016) Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150(4):789–798
39. Chan R, Misirovs R, Lipworth B (2021) Repeatability of impulse oscillometry in patients with severe asthma. Eur Respir J 59(1):2101679
40. Murphy K, Jacobs J, Bjørner L et al (2017) Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 5(6):1572–81.e3
41. Virchow JC, Hickey L, Du E, Garin M (2020) In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV(1) reversibility. Allergy Asthma Clin Immunol 16:26
42. Nolasco S, Crimi C, Pelaia C et al (2021) Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract 9(12):4371–80.e4
43. Pelaia C, Busceti MT, Crimi C et al (2020) Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother 129:110444
44. Shirai T, Akamatsu T, Hirai K et al (2020) Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma. Allergy 75(10):2678–2680
45. Harb H, Chatila TA (2020) Mechanisms of dupilumab. Clin Exp Allergy 50(1):5–14
46. Manson ML, Säfholm J, James A et al (2020) IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol Pract 14(3):808–17.e2
47. Castro M, Rabe KF, Corren J et al (2020) Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res 6(1):00204–02019
48. Wechsler ME, Ruddy MK, Pavord ID et al (2021) Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med 385(18):1656–1668
49. Pelaia C, Lombardo N, Busceti MT et al (2021) Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy 14:1165–1172
50. Minagawa S, Araya J, Watanabe N et al (2022) Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP. BMC Pulm Med 22(1):258
51. Manoharan A, Anderson WJ, Lipworth J, Ibrahim I, Lipworth BJ (2014) Small airway dysfunction is associated with poorer asthma control. Eur Respir J 44(5):1353–1355

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.